Centene Buy Rating Raised, Target Jumps to $80 on 2028 Earnings Outlook
Analysts upgraded Centene to Buy from Hold and raised its price target from $53 to $80, valuing shares at 12 times projected 2028 earnings of $6.70 per share. The outlook reflects expected margin recovery after cost pressures ease, driven by peaked healthcare utilization and disciplined underwriting.
1. Analysts Upgrade and Price Target Increase
Centene was upgraded from Hold to Buy with its price target lifted from $53 to $80, based on a 12x multiple of projected 2028 earnings of $6.70 per share.
2. Valuation Multiple Adjustment
The valuation multiple was reduced from 15x to 12x to account for a longer timeline for earnings recovery beyond 2027 while still reflecting confidence in steady growth by 2028.
3. Expected Margin Recovery Drivers
Analysts expect healthcare utilization trends have peaked, enabling Centene to manage medical cost inflation through disciplined pricing and stronger underwriting practices.
4. Remaining Risks and Challenges
Key challenges include controlling Medicare and Medicaid cost pressures and sustaining margin expansion amid potential shifts in utilization patterns or regulatory changes.